Disease relevance of L 6150

• Hemodynamic effects of oxdralazine and hydralazine in hypertension [1].

High impact information on L 6150

• The triple regimen reduced blood pressure 35/15 mm Hg after one month (daily doses 25 mg chlorthalidone, 20 mg oxdralazine, 40 mg propranolol), and further increase in dosages caused a reduction of 45/24 mm Hg at the third month (daily doses 25 mg chlorthalidone, 56 +/- 20 mg oxdralazine, 112 +/- 40 mg propranolol) [2].
• This combination seems particularly successful since propranolol will prevent the undesired rise in cardiac output due to oxdralazine as well as the activation of the renin-angiotensin axis due to diuretics [3].
• Blood pressure did not return to normal limits in 15 patients, who were continued on the same protocol plus 10 to 50 mg oxdralazine q.d. After an average of 68 +/- 35 days blood pressure fell from 180/110 mm Hg to 145/90 mm Hg without orthostatism, significant side effects, or changes in GFR [3].
• Effect of 3-hydrazino-6[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) on renin in hypertensive rats [4].

Chemical compound and disease context of L 6150

• Comparative study of oxdralazine and dihydralazine in essential hypertension [5].

Associations of L 6150 with other chemical compounds

• After 6 months, 10/15 patients on oxdralazine and 7/16 patients on dihydralazine had achieved a stabile diastolic pressure below 95 mmHg [5].

References